Short answer
Foghorn Therapeutics Inc. (FHTX) filed an 8-K current report with the SEC on April 21, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Investor presentation dated April 2026 furnished under Regulation FD.
Foghorn Therapeutics Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Investor presentation dated April 2026 furnished under Regulation FD
- Materials intended for investor meetings and presentations
- Potentially market-relevant updates contained in Exhibit 99.1
Item 8.01 · Other Events
- AACR 2026 preclinical data spans FHD-909 and selective CBP, EP300, and ARID1B degrader programs
- Multiple discovery programs could broaden Foghorn’s oncology pipeline beyond current clinical candidates
- Data are preclinical, leaving efficacy, safety, regulatory, and clinical-translatability risks unresolved
- Detailed findings and management commentary appear in Exhibit 99.2’s press release
Item EX-99.1 · Exhibit EX-99.1
- FHD-909 plus anti-PD-1 produced complete, durable tumor regression in syngeneic mouse models
- Tumor rejection after rechallenge suggests treatment-induced anti-tumor immune memory
- FHT-171 showed strong monotherapy activity and favorable tolerability in heavily pretreated ER+ breast cancer PDX models
- Selective EP300 degraders delivered complete responses and superior efficacy versus inobrodib in preclinical multiple myeloma models
- Cereblon-based ARID1B degraders achieved robust degradation with potential oral bioavailability
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Foghorn Therapeutics Inc. 8-K filings
Get the next FHTX 8-K as it lands
Follow FHTX for push alerts, or ask the research agent what this filing means.